Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Tirzepatide (marketed as Mounjaro and Zepbound) is a first-in-class dual GIP/GLP-1 receptor agonist developed by Eli Lilly that has demonstrated the largest body weight reductions of any approved anti-obesity pharmacotherapy, with up to 20.9% mean weight loss in clinical trials
Tirzepatide (Eli Lilly): Dual GLP-1/GIP agonist
-Arrestins Role : The role of -arrestin in the desensitization of GLP-1 and GIP receptors and its impact on the long-term efficacy and safety of receptor agonists are still being explored
This includes both your weight change and any side effects you may be experiencing
US$ 22.66
US$ 28.27
US$ 26.28
US$ 20.42
US$ 23.85
US$ 27.65
US$ 27.23
US$ 23.19
US$ 22.60
US$ 24.91
